美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Niagen Bioscience

3.21

0.0000

盤前：3.350.1400+4.36%04:43 EDT

成交量：41.57萬

成交額：134.09萬

市值：2.56億

市盈率：16.88

高：3.28

開：3.21

低：3.19

收：3.21

52周最高：10.52

52周最低：2.87

股本：7,964.43萬

流通股本：5,581.92萬

量比：0.76

換手率：0.74%

股息：- -

股息率：- -

每股收益(TTM):0.1901

每股收益(LYR):0.2000

淨資產收益率：21.80%

總資產收益率：5.44%

市淨率：3.10

市盈率(LYR):16.05

資料載入中...

總覽公司新聞資訊公告

Niagen Bioscience：部分商業夥伴持續面臨激烈競爭，原料業務預計不及上年

Niagen Bioscience預計：Niagen Plus增長與新護膚合作將從2027年起成重要驅動力

Niagen Bioscience將於8月4日發布二季度財報

环球市场播报

Niagen股價上漲，因其候選藥物獲美國和歐盟罕見病認定

Niagen Bioscience旗下NB4168獲美國FDA授予罕見兒科疾病認定及歐洲EMA孤兒藥產品認定，用於治療共濟失調毛細血管擴張症

Niagen Bioscience根據2026年6月26日銷售協議可能出售至多5000萬美元普通股 - 美國證券交易委員會文件披露

Niagen Bioscience強化NAD+全球領導地位外部研究項目更名

环球市场播报

國家廣告審查委員會建議Niagen修改或停止部分Tru Niagen NAD+膳食補充劑宣傳主張

Niagen Bioscience將Olympia Pharmaceuticals納入Niagen Plus™ 503B複合藥物合作伙伴網絡

Niagen Bioscience攜手USP制定首個NRCL專論，確立Niagen®專利成分標準

Niagen Bioscience與OneSpaWorld達成首項郵輪診所合作，將NAD+增強型Niagen IV療法引入遠洋航行

Niagen Bioscience與全球頂尖機構就Niagen®達成逾300項外部研究協議，助力45項臨床研究發表

Niagen Bioscience 2025財年淨銷售額按年增長30%至1.294億美元，淨利潤激增103%至1740萬美元，基本每股收益0.22美元

Niagen Bioscience通過全現金交易向LGC出售Chromadex參考標準業務，精簡運營聚焦主業

BUZZ-Niagen Bioscience 股價因注射用 NAD+ 增效劑的美國專利而上漲

Niagen Bioscience公司獲得煙酰胺核苷靜脈注射與注射製劑及使用方法的新美國專利

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/NAGE/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":3.21,"timestamp":1787601600000,"preClose":3.21,"halted":0,"volume":415746,"hourTrading":{"tag":"盘前","latestPrice":3.35,"preClose":3.21,"latestTime":"04:43 EDT","volume":184,"amount":598.9199264,"timestamp":1787647385775,"change":0.14,"changeRate":0.043614,"amplitude":0.158879},"delay":0,"changeRate":0,"floatShares":55819168,"shares":79644327,"eps":0.190148,"marketStatus":"盤前交易","change":0,"latestTime":"08-25 04:43:13 EDT","open":3.21,"high":3.28,"low":3.19,"amount":1340921.0811258,"amplitude":0.028037,"askPrice":3.5,"askSize":48,"bidPrice":3.2,"bidSize":1,"shortable":3,"etf":0,"ttmEps":0.190148,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":3.21,"preHourTrading":{"tag":"盘前","latestPrice":3.35,"preClose":3.21,"latestTime":"04:43 EDT","volume":184,"amount":598.9199264,"timestamp":1787647385775,"change":0.14,"changeRate":0.043614,"amplitude":0.158879},"postHourTrading":{"tag":"盘后","latestPrice":3.21,"preClose":3.21,"latestTime":"19:30 EDT","volume":1693,"amount":5435.84,"timestamp":1787614203345,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7560486291342426,"impliedVol":0.8647,"impliedVolPercentile":0.192},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","floatShares":55819168,"roa":"5.44%","roe":"21.80%","lyrEps":0.2,"volumeRatio":0.7560486291342426,"shares":79644327,"dividePrice":0,"high":3.28,"amplitude":0.028037,"preClose":3.21,"low":3.19,"week52Low":2.87,"pbRate":"3.10","psRate":"1.98","week52High":10.52,"institutionHeld":0,"latestPrice":3.21,"committee":-0.959184,"eps":0.190148,"divideRate":0,"volume":415746,"delay":0,"ttmEps":0.190148,"open":3.21,"prevYearClose":6.36,"prevWeekClose":3.21,"prevMonthClose":3.4,"prevQuarterClose":3.19,"fiveDayClose":3.04,"twentyDayClose":3.23,"sixtyDayClose":3.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"NAGE","fiscalQuarterEnding":"2026/06","expectedEps":0.01,"name":null,"time":"盤後","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"post","actualEps":0.01},{"market":"US","date":"2026-05-06","symbol":"NAGE","fiscalQuarterEnding":"2026/03","expectedEps":0.06,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":0.07},{"market":"US","date":"2026-03-04","symbol":"NAGE","fiscalQuarterEnding":"2025/12","expectedEps":0.02,"name":null,"time":"盤後","type":"earning","dateTimestamp":1772600400000,"reportTimeType":"post","actualEps":0.03},{"market":"US","date":"2025-11-04","symbol":"NAGE","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-08-06","symbol":"NAGE","fiscalQuarterEnding":"2025/06","expectedEps":0.02,"name":null,"time":"盤後","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":0.04}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1783569600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAGE","date":"2026-08-24","current":16.881587,"percent":0.165266,"low":13.660897,"twenty":17.931144,"median":26.20764,"eighty":56.295844,"high":80.643552,"avg":35.568103,"sd":19.71446,"marketCap":254530536},"quantilePoints":[{"date":"2025-03-21","current":69.624479,"twenty":69.806742,"median":70.080136,"eighty":70.353531,"marketCap":595289295},{"date":"2025-03-28","current":67.346191,"twenty":68.676711,"median":69.624479,"eighty":70.371757,"marketCap":575809933},{"date":"2025-04-04","current":60.420196,"twenty":62.662031,"median":67.938546,"eighty":69.697384,"marketCap":516592673},{"date":"2025-04-11","current":51.67157,"twenty":54.861173,"median":62.880747,"eighty":69.551574,"marketCap":441791924},{"date":"2025-04-17","current":59.600012,"twenty":54.815607,"median":61.696037,"eighty":69.259953,"marketCap":509580103},{"date":"2025-04-25","current":67.255059,"twenty":55.043436,"median":62.151694,"eighty":68.530901,"marketCap":575030758},{"date":"2025-05-02","current":68.895427,"twenty":55.954751,"median":62.880747,"eighty":69.442216,"marketCap":589055899},{"date":"2025-05-09","current":51.710369,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"marketCap":729374756},{"date":"2025-05-16","current":58.761783,"twenty":54.815607,"median":62.789615,"eighty":69.71561,"marketCap":828834951},{"date":"2025-05-23","current":56.859021,"twenty":55.043436,"median":61.650471,"eighty":69.624479,"marketCap":801996485},{"date":"2025-05-30","current":60.552618,"twenty":55.242319,"median":61.364091,"eighty":69.478669,"marketCap":854094682},{"date":"2025-06-06","current":64.414107,"twenty":55.822209,"median":61.604905,"eighty":69.296406,"marketCap":908560979},{"date":"2025-06-13","current":79.132535,"twenty":56.409541,"median":62.698483,"eighty":70.55402,"marketCap":1116164400},{"date":"2025-06-20","current":77.117845,"twenty":56.623974,"median":63.647427,"eighty":71.912091,"marketCap":1087747202},{"date":"2025-06-27","current":77.341699,"twenty":56.791865,"median":65.523561,"eighty":75.181504,"marketCap":1090904668},{"date":"2025-07-03","current":71.129739,"twenty":57.426855,"median":65.645306,"eighty":75.483707,"marketCap":1003284974},{"date":"2025-07-11","current":65.981088,"twenty":58.471876,"median":66.48476,"eighty":75.192697,"marketCap":930663244},{"date":"2025-07-18","current":57.950311,"twenty":58.471876,"median":65.645306,"eighty":75.114348,"marketCap":817389135},{"date":"2025-07-25","current":51.87826,"twenty":56.758286,"median":65.022337,"eighty":74.190401,"marketCap":731742856},{"date":"2025-08-01","current":52.325969,"twenty":55.224884,"median":64.358143,"eighty":72.732275,"marketCap":738057789},{"date":"2025-08-08","current":43.320593,"twenty":54.318273,"median":62.947882,"eighty":72.15947,"marketCap":768030786},{"date":"2025-08-15","current":43.771379,"twenty":53.985743,"median":62.607352,"eighty":71.628921,"marketCap":776022782},{"date":"2025-08-22","current":44.041851,"twenty":52.415511,"median":61.650471,"eighty":71.37484,"marketCap":780817979},{"date":"2025-08-29","current":44.267244,"twenty":51.68709,"median":61.280145,"eighty":71.129739,"marketCap":784813977},{"date":"2025-09-05","current":42.013311,"twenty":50.71606,"median":60.552618,"eighty":71.083855,"marketCap":744853999},{"date":"2025-09-12","current":43.365671,"twenty":45.745824,"median":60.318517,"eighty":70.845641,"marketCap":768829986},{"date":"2025-09-19","current":45.709762,"twenty":45.222912,"median":59.50888,"eighty":70.6087,"marketCap":810388363},{"date":"2025-09-26","current":42.419019,"twenty":45.024566,"median":58.520194,"eighty":70.371757,"marketCap":752046795},{"date":"2025-10-03","current":33.268051,"twenty":44.46559,"median":56.887002,"eighty":69.697384,"marketCap":589809282},{"date":"2025-10-10","current":34.079467,"twenty":44.02382,"median":56.607185,"eighty":69.623328,"marketCap":604194874},{"date":"2025-10-17","current":33.448366,"twenty":43.66319,"median":55.29204,"eighty":69.583421,"marketCap":593006080},{"date":"2025-10-24","current":33.448366,"twenty":43.41075,"median":54.929521,"eighty":69.405763,"marketCap":593006080},{"date":"2025-10-31","current":32.050928,"twenty":43.28453,"median":54.228731,"eighty":69.187048,"marketCap":568230894},{"date":"2025-11-07","current":25.87441,"twenty":42.455082,"median":54.050915,"eighty":68.822522,"marketCap":528588317},{"date":"2025-11-14","current":27.403352,"twenty":42.022327,"median":53.333314,"eighty":68.390298,"marketCap":559823081},{"date":"2025-11-21","current":26.30565,"twenty":34.151593,"median":52.437896,"eighty":67.731548,"marketCap":537398122},{"date":"2025-11-28","current":26.540872,"twenty":33.854074,"median":52.018169,"eighty":67.346191,"marketCap":542203471},{"date":"2025-12-05","current":26.266446,"twenty":33.628681,"median":51.67157,"eighty":67.255059,"marketCap":536597231},{"date":"2025-12-12","current":25.992021,"twenty":33.448366,"median":50.903505,"eighty":67.255059,"marketCap":530990991},{"date":"2025-12-19","current":25.482373,"twenty":32.772186,"median":49.393282,"eighty":66.988433,"marketCap":520579403},{"date":"2025-12-26","current":25.913613,"twenty":32.474667,"median":46.160548,"eighty":66.182557,"marketCap":529389208},{"date":"2026-01-02","current":24.933522,"twenty":30.002996,"median":45.709762,"eighty":65.94751,"marketCap":509366924},{"date":"2026-01-09","current":25.717595,"twenty":27.520963,"median":45.43929,"eighty":65.757233,"marketCap":525384751},{"date":"2026-01-16","current":24.737504,"twenty":27.019156,"median":45.168818,"eighty":65.594939,"marketCap":505362467},{"date":"2026-01-23","current":24.619893,"twenty":26.909386,"median":44.627874,"eighty":65.546241,"marketCap":502959792},{"date":"2026-01-30","current":23.482987,"twenty":26.540872,"median":44.492638,"eighty":65.122582,"marketCap":479733942},{"date":"2026-02-06","current":20.111473,"twenty":26.282128,"median":44.267244,"eighty":64.478311,"marketCap":410857283},{"date":"2026-02-13","current":19.954658,"twenty":25.944976,"median":44.008043,"eighty":64.391721,"marketCap":407653717},{"date":"2026-02-20","current":19.366604,"twenty":25.843047,"median":43.816458,"eighty":64.134289,"marketCap":395640346},{"date":"2026-02-27","current":20.307491,"twenty":25.623506,"median":43.591065,"eighty":63.1941,"marketCap":414861740},{"date":"2026-03-06","current":23.545172,"twenty":25.529418,"median":43.41075,"eighty":62.988163,"marketCap":409262188},{"date":"2026-03-13","current":22.252496,"twenty":25.411807,"median":43.320593,"eighty":62.862521,"marketCap":386792892},{"date":"2026-03-20","current":21.88316,"twenty":25.058974,"median":43.095199,"eighty":62.753162,"marketCap":380373093},{"date":"2026-03-27","current":20.636651,"twenty":24.761026,"median":42.599334,"eighty":62.487416,"marketCap":358706271},{"date":"2026-04-02","current":20.867486,"twenty":24.619893,"median":42.419019,"eighty":62.007672,"marketCap":362718645},{"date":"2026-04-10","current":20.682818,"twenty":24.345467,"median":42.035851,"eighty":61.696037,"marketCap":359508746},{"date":"2026-04-17","current":21.836993,"twenty":23.875024,"median":35.567063,"eighty":61.604905,"marketCap":379570618},{"date":"2026-04-24","current":21.836993,"twenty":23.545172,"median":34.102007,"eighty":61.448036,"marketCap":379570618},{"date":"2026-05-01","current":21.836993,"twenty":23.175836,"median":33.854074,"eighty":61.280145,"marketCap":379570618},{"date":"2026-05-08","current":18.041368,"twenty":22.760333,"median":33.696298,"eighty":61.168218,"marketCap":336236974},{"date":"2026-05-15","current":16.273169,"twenty":22.34483,"median":33.493445,"eighty":60.552618,"marketCap":303283042},{"date":"2026-05-22","current":16.230344,"twenty":22.248072,"median":33.448366,"eighty":60.552618,"marketCap":302484929},{"date":"2026-05-29","current":16.444465,"twenty":22.012428,"median":33.155355,"eighty":60.44668,"marketCap":306475495},{"date":"2026-06-05","current":14.988445,"twenty":21.873927,"median":32.772186,"eighty":60.257509,"marketCap":279339644},{"date":"2026-06-12","current":14.688676,"twenty":21.735571,"median":32.546792,"eighty":59.723377,"marketCap":273752851},{"date":"2026-06-18","current":14.431731,"twenty":21.468256,"median":32.208703,"eighty":59.545333,"marketCap":268964171},{"date":"2026-06-26","current":14.174786,"twenty":20.98752,"median":28.148222,"eighty":59.396403,"marketCap":264175492},{"date":"2026-07-02","current":14.260435,"twenty":20.867486,"median":27.834592,"eighty":59.097565,"marketCap":265771718},{"date":"2026-07-10","current":14.945621,"twenty":20.636651,"median":27.324945,"eighty":58.568512,"marketCap":278541531},{"date":"2026-07-17","current":14.560203,"twenty":20.370149,"median":27.050519,"eighty":58.147287,"marketCap":271358511},{"date":"2026-07-24","current":13.660897,"twenty":20.127155,"median":26.95251,"eighty":57.524987,"marketCap":254598133},{"date":"2026-07-31","current":14.21761,"twenty":20.033066,"median":26.893705,"eighty":56.881406,"marketCap":264973605},{"date":"2026-08-07","current":15.07415,"twenty":19.767151,"median":26.540872,"eighty":56.825443,"marketCap":241050726},{"date":"2026-08-14","current":15.123736,"twenty":19.424638,"median":26.403659,"eighty":56.657552,"marketCap":241843656},{"date":"2026-08-21","current":15.619596,"twenty":18.243689,"median":26.266446,"eighty":56.409541,"marketCap":249772956},{"date":"2026-08-24","current":15.917112,"twenty":17.931144,"median":26.20764,"eighty":56.295844,"marketCap":254530536}],"updateTime":1787647393634},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAGE\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1155120533","title":"Niagen Bioscience：部分商業夥伴持續面臨激烈競爭，原料業務預計不及上年","url":"https://stock-news.laohu8.com/highlight/detail?id=1155120533","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155120533?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:20","pubTimestamp":1785874850,"startTime":"0","endTime":"0","summary":"Niagen Bioscience 发布预警：由于部分商业合作伙伴继续在竞争更加激烈的市场中挣扎，公司原料业务板块的业绩预计将低于去年同期水平。这一预期意味着，外部市场环境的恶化正在对公司的核心业务造成显著压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128164693","title":"Niagen Bioscience預計：Niagen Plus增長與新護膚合作將從2027年起成重要驅動力","url":"https://stock-news.laohu8.com/highlight/detail?id=1128164693","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128164693?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 04:17","pubTimestamp":1785874648,"startTime":"0","endTime":"0","summary":"Niagen Bioscience对外释放积极信号，表示其旗舰产品Niagen Plus的持续增长以及一系列全新的护肤品战略合作，预计将从2027年开始，逐步转化为公司业绩中举足轻重的贡献者。这一预期标志着公司对未来增长引擎的清晰布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653036272","title":"Niagen Bioscience將於8月4日發布二季度財報","url":"https://stock-news.laohu8.com/highlight/detail?id=2653036272","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653036272?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 21:46","pubTimestamp":1784641560,"startTime":"0","endTime":"0","summary":"专注于NAD+与健康老龄化科学的Niagen Bioscience公司宣布，将于2026年8月4日（周二）美股盘后公布第二季度财务业绩。公司将于当天下午4点30分举行网络直播会议，讨论财报结果并更新业务进展。　　公司此前发布的第一季度财报显示，总净销售额增长3%至3150万美元，其中Tru Niagen产品贡献2240万美元。公司近期在产品线拓展方面取得多项进展：推出了Niagen Plus居家注射套装及远程医疗功能，并试水了Niagen NanoCloud护肤产品线，预计10月全面推广。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-21/doc-iniiqquw9233142.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSET","SQMX","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651774111","title":"Niagen股價上漲，因其候選藥物獲美國和歐盟罕見病認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2651774111","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651774111?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 20:50","pubTimestamp":1783947000,"startTime":"0","endTime":"0","summary":"BUZZ-Niagen股价上涨，因其候选药物获美国和欧盟罕见病认定7月13日-** 生物技术公司Niagen Bioscience（NAGE.O）的股价在盘前交易中上涨2.6%，至3.47美元** 该公司表示，其试验性药物NB4168已获得美国和欧洲针对共济失调-毛细血管扩张症的罕见病认定，该病是一种罕见的遗传性疾病，会影响运动功能、削弱免疫系统并增加患癌风险** 公司表示，这些认定提供了监管激励","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nL4T43F12T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138170641","title":"Niagen Bioscience旗下NB4168獲美國FDA授予罕見兒科疾病認定及歐洲EMA孤兒藥產品認定，用於治療共濟失調毛細血管擴張症","url":"https://stock-news.laohu8.com/highlight/detail?id=1138170641","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138170641?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 20:32","pubTimestamp":1783945941,"startTime":"0","endTime":"0","summary":"生物技术公司Niagen Bioscience宣布，其候选药物NB4168用于治疗共济失调毛细血管扩张症（A-T）的研发，已获得美国食品药品监督管理局（FDA）授予的罕见儿科疾病（RPD）认定，以及欧洲药品管理局（EMA）授予的孤儿药产品（OMPD）认定。这两项认定标志着该药物在针对这一严重罕见疾病的开发进程中取得了重要监管进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160802853","title":"Niagen Bioscience根據2026年6月26日銷售協議可能出售至多5000萬美元普通股 - 美國證券交易委員會文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1160802853","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160802853?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 18:20","pubTimestamp":1782728418,"startTime":"0","endTime":"0","summary":"根据一份向美国证券交易委员会提交的文件，Niagen Bioscience公司依据一份日期为2026年6月26日的股权销售协议，可能出售价值高达5000万美元的公司普通股。该协议为公司提供了通过市场运作，在特定时期内逐步出售股票以筹集资金的途径。此举通常旨在为公司的运营、研发或其他企业活动提供资金支持，同时根据市场条件和公司需求灵活执行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640941274","title":"Niagen Bioscience強化NAD+全球領導地位 外部研究項目更名","url":"https://stock-news.laohu8.com/highlight/detail?id=2640941274","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640941274?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 23:09","pubTimestamp":1780412940,"startTime":"0","endTime":"0","summary":"NAD+科学领域的全球权威企业Niagen Bioscience宣布，将其广受认可的“ChromaDex外部研究项目”正式更名为“Niagen研究项目”。此举紧随公司从ChromaDex更名为Niagen Bioscience的战略步伐，旨在通过其旗舰成分Niagen，集中力量推进对NAD+的理解与应用。　　此外，公司还启动了“Niagen Bioscience培训生资助计划”，每年将向专注于运动表现、恢复、疲劳及适应性等方向的研究生和博士后提供三项1万美元的资助，以培养下一代NAD+科研人才。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumh2976932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4121","NAGE","BK4183","NAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124900345","title":"國家廣告審查委員會建議Niagen修改或停止部分Tru Niagen NAD+膳食補充劑宣傳主張","url":"https://stock-news.laohu8.com/highlight/detail?id=1124900345","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124900345?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 22:32","pubTimestamp":1779373939,"startTime":"0","endTime":"0","summary":"国家广告审查委员会已提出建议，要求Niagen公司对其Tru Niagen NAD+膳食补充剂的某些宣传主张进行修改或完全停止使用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115416670","title":"Niagen Bioscience將Olympia Pharmaceuticals納入Niagen Plus™ 503B複合藥物合作伙伴網絡","url":"https://stock-news.laohu8.com/highlight/detail?id=1115416670","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115416670?lang=zh_tw&edition=fundamental","pubTime":"2026-04-28 20:37","pubTimestamp":1777379832,"startTime":"0","endTime":"0","summary":"Niagen Bioscience宣布与Olympia Pharmaceuticals达成合作，后者正式加入其503B复合药物合作伙伴网络，共同推进明星产品Niagen Plus™的市场布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115891551","title":"Niagen Bioscience攜手USP制定首個NRCL專論，確立Niagen®專利成分標準","url":"https://stock-news.laohu8.com/highlight/detail?id=1115891551","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115891551?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 20:33","pubTimestamp":1775737993,"startTime":"0","endTime":"0","summary":"Niagen Bioscience与美国药典委员会（USP）达成合作，共同为氯化烟酰胺核糖（NRCL）——即Niagen®的专利形式——制定史上首个USP专论。这一里程碑式的合作旨在为NRCL建立权威的质量与纯度标准，为行业提供统一规范。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100336940","title":"Niagen Bioscience與OneSpaWorld達成首項郵輪診所合作，將NAD+增強型Niagen IV療法引入遠洋航行","url":"https://stock-news.laohu8.com/highlight/detail?id=1100336940","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100336940?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 20:35","pubTimestamp":1774960546,"startTime":"0","endTime":"0","summary":"Niagen Bioscience宣布与OneSpaWorld Holdings Limited达成首项邮轮诊所合作，将NAD+增强型Niagen IV疗法的健康益处带入远洋航行体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSW","LU0029874061.USD","LU0128526141.USD","BK4183","NAGE","BK4121","BK4192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171944922","title":"Niagen Bioscience與全球頂尖機構就Niagen®達成逾300項外部研究協議，助力45項臨床研究發表","url":"https://stock-news.laohu8.com/highlight/detail?id=1171944922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171944922?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 20:32","pubTimestamp":1773750774,"startTime":"0","endTime":"0","summary":"Niagen Bioscience近日宣布，其与全球多家顶尖科研机构就核心成分Niagen®签署的外部研究协议已突破300项。这一重要进展进一步推动了相关临床研究的发展，目前已有45项基于Niagen®的临床研究在权威期刊上正式发表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142110680","title":"Niagen Bioscience 2025財年淨銷售額按年增長30%至1.294億美元，淨利潤激增103%至1740萬美元，基本每股收益0.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142110680","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142110680?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658211,"startTime":"0","endTime":"0","summary":"Niagen Bioscience（股票代码：NAGE）近日公布了其2025财年财务业绩，表现亮眼。公司净销售额达到1.294亿美元，较去年同期大幅增长30%。盈利能力方面更是实现飞跃，净利润录得1740万美元，同比飙升103%。按基本每股收益计算，该公司2025财年实现每股收益0.22美元。\n这一强劲的增长势头主要得益于核心产品在市场中的需求持续旺盛以及公司运营效率的显著提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104837583","title":"Niagen Bioscience通過全現金交易向LGC出售Chromadex參考標準業務，精簡運營聚焦主業","url":"https://stock-news.laohu8.com/highlight/detail?id=1104837583","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104837583?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 20:10","pubTimestamp":1772107856,"startTime":"0","endTime":"0","summary":"Niagen Bioscience宣布将旗下Chromadex参考标准业务以全现金交易方式出售给LGC，旨在优化公司架构并集中资源发展核心业务。此次交易将帮助Niagen Bioscience进一步聚焦主营业务，提升运营效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614038784","title":"BUZZ-Niagen Bioscience 股價因注射用 NAD+ 增效劑的美國專利而上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2614038784","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614038784?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 22:13","pubTimestamp":1772028829,"startTime":"0","endTime":"0","summary":"BUZZ-Niagen Bioscience 股价因注射用 NAD+ 增效剂的美国专利而上涨2月25日 - ** 制药商Niagen Bioscience NAGE.O股价盘前上涨3.3%至5.28美元** 该公司表示，它获得了一项新的美国专利，涵盖其NAD+促进成分Niagen的静脉注射和注射版本** Niagen是一种烟酰胺核苷，是一种维生素B3衍生物，用于提高NAD+水平，有助于支持细胞能量和修复，该公司称。** Niagen IV 已在超过 1,200 家诊所提供；公司称，新配方能更有效地提供 NAD+，且副作用更少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4S3ZL1ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114396120","title":"Niagen Bioscience公司獲得煙酰胺核苷靜脈注射與注射製劑及使用方法的新美國專利","url":"https://stock-news.laohu8.com/highlight/detail?id=1114396120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114396120?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 21:37","pubTimestamp":1772026632,"startTime":"0","endTime":"0","summary":"Niagen Bioscience公司宣布，已成功获得一项新的美国专利，该专利涵盖了烟酰胺核苷的静脉注射制剂、注射制剂及其使用方法。这一专利的授予进一步巩固了该公司在相关技术领域的知识产权布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4183","NAGE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}